Form 4: Leap Therapeutics Executive Settles Restricted Stock Units

John Mark O'Mahony, Chief Manufacturing Officer of Leap Therapeutics, settled 22,500 Restricted Stock Units (RSUs) on March 28, 2025, receiving an equivalent number of common stock shares.

Summary

• On March 28, 2025, John Mark O'Mahony, the Chief Manufacturing Officer of Leap Therapeutics, settled 22,500 Restricted Stock Units (RSUs) that were previously granted on January 31, 2022.
• The settlement resulted in the issuance of 22,500 shares of Leap Therapeutics' common stock to O'Mahony.
• The RSUs had fully vested on January 31, 2025, but the settlement was deferred by the Compensation Committee until March 28, 2025.
• This deferral was due to potential limitations under the company's insider trading policy that might have restricted O'Mahony from selling all underlying shares on the vesting date.
• The share numbers have been adjusted to reflect a 10-for-1 reverse stock split that occurred on June 20, 2023.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency into insider transactions.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates the settlement of previously granted equity compensation.

Stakeholder Impact

• The settlement of RSUs impacts shareholders by increasing the number of outstanding shares, although the effect is likely minimal given the relatively small number of shares involved.

Key Dates

Keywords

Restricted Stock Units, RSUs, Form 4, Insider Trading, LEAP Therapeutics, LPTX, Stock Settlement, John Mark O'Mahony, Compensation Committee, Reverse Stock Split